Rexahn could take in $40 million through at-the-market stock offering

MLV helps raise funds for working capital, general corporate purposes

By Toni Weeks

San Luis Obispo, Calif., March 16 – Rexahn Pharmaceuticals, Inc. could raise $40 million through an at-the-market offering of its common stock via agent MLV & Co. LLC, according to a 424B5 filing with the Securities and Exchange Commission.

The agent will earn a fee of 3%.

Proceeds will be used for working capital and general corporate purposes, including development of the company’s product candidates and general and administrative expenses.

Rexahn is a biopharmaceutical company based in Rockville, Md.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.